Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05965206 · ClinicalTrials.gov registry record
Implementation of a Pharmacist-Based, Post-Chemotherapy Follow-up Clinic
A clinical trial, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- 40
- Enrollment target
NCT05965206: Completed study, sponsored by Cedars-Sinai Medical Center.
NCT05965206 is a clinical trial that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05965206 has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the impact of pharmacists on reducing chemotherapy-related side effects by providing education before and after patients receive intravenous chemotherapy at one of Cedars-Sinai outpatient infusion centers. Participants will be interviewed via telephone within 7 business days after receiving intravenous chemotherapy from the outpatient cancer center infusion clinic.
Primary Outcome
Number of hospital admission related to chemotherapy
Interventions
- BEHAVIORAL Follow-up phone interview
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-07-20 |
| Est. Completion | 2025-04-30 |
What the finished NCT05965206 record still lists
NCT05965206 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Follow-up phone interview is the first listed.
NCT05965206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05965206 about?
NCT05965206 is a clinical study titled "Implementation of a Pharmacist-Based, Post-Chemotherapy Follow-up Clinic". The purpose of this study is to determine the impact of pharmacists on reducing chemotherapy-related side effects by providing education before and after patients receive intravenous chemotherapy at one of Cedars-Sinai outpatient infusion centers. Participants will be interviewed via telephone with...
What is the current status of trial NCT05965206?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2024-07-20. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT05965206?
The interventions under investigation include: Follow-up phone interview (BEHAVIORAL).
Who is sponsoring clinical trial NCT05965206?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI